Boehringer Ingelheim and MacroGenics have entered into a partnership to develop and commercialise antibody-based therapeutics covering multiple therapeutic areas such as immunology, respiratory, oncology and infectious diseases.

MacroGenics’ Dual-Affinity Re-Targeting (DART) platform will be used for the development of drug candidates, which will be directed against up to ten combinations of molecular targets.

The DART platform allows for the generation of highly stable antibody-based therapeutic molecules capable of targeting two antigens simultaneously.

The two companies will share responsibility for discovery and certain pre-clinical activities, and Boehringer Ingelheim will be responsible for all subsequent clinical, regulatory, commercial and manufacturing activities for any DART-based product resulting from the collaboration.

During the first three years of collaboration, MacroGenics may receive payments totalling up to $60m, which includes an upfront cash payment, annual maintenance fees, R&D funding and near-term research-based milestones.

Boehringer expects to make a future equity investment in MacroGenics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Depending upon the development, regulatory and commercial milestones, MacroGenics may receive up to $210m for each of the ten DART programmes.

MacroGenics may also receive tiered royalties on net product sales, and can choose to co-promote certain DART products in the US.